Novel dendritic cell-based vaccination in late stage melanoma

References

• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012; PMID:15342808; http://dx.doi.org/10.1056/NEJMra041245
   PubMed Web of Science ®Google Scholar
• DR P. EA G. Cytokines: biology and applications in cancer medicine. In: al JHEFIRBJe, ed. Cancer Medicine 4th Editions, 1997:1213-26.
   Google Scholar
• Philip PA, Flaherty L. Treatment of malignant melanoma with interleukin-2. Semin Oncol 1997; 24(Suppl 4):S32-8; PMID:9122732
   PubMedGoogle Scholar
• Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-8; PMID:18765555; http://dx.doi.org/10.1158/1078-0432.CCR-08-0116
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1):S11-4; PMID:10685652
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7:827-35; PMID:8922197; http://dx.doi.org/10.1093/oxfordjournals.annonc.a010762
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-9; PMID:9586888
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames P, Shinn K, Kim H, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002; 8:2775-81; PMID:12231516
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008; 26:5748-54; PMID:19001327; http://dx.doi.org/10.1200/JCO.2008.17.5448
   PubMed Web of Science ®Google Scholar
• Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25:5426-34; PMID:18048825; http://dx.doi.org/10.1200/JCO.2007.12.0253
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006; 17:571-7; PMID:16469753; http://dx.doi.org/10.1093/annonc/mdl007
   PubMed Web of Science ®Google Scholar
• Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23:6747-55; PMID:16170182; http://dx.doi.org/10.1200/JCO.2005.03.202
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, et al.; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002; 20:1600-7; PMID:11896110; http://dx.doi.org/10.1200/JCO.20.6.1600
   PubMed Web of Science ®Google Scholar
• NCCN Practical Guidelines in Oncology: Melanoma. National Comprehensive Cancer Network 2014; Version 3.2014.
   Google Scholar
• Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866-9; PMID:11567700; http://dx.doi.org/10.1016/S0140-6736(01)06068-8
   PubMed Web of Science ®Google Scholar
• Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22:53-61; PMID:14665609; http://dx.doi.org/10.1200/JCO.2004.03.185
   PubMed Web of Science ®Google Scholar
• Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H, et al.; Austrian malignant melanoma cooperative group. adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16:1425-9; PMID:9552047
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, et al.; French Cooperative Group on Melanoma. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351:1905-10; PMID:9654256; http://dx.doi.org/10.1016/S0140-6736(97)12445-X
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17; PMID:8558223
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-58; PMID:10856105
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U; Eastern Cooperative Oncology Group. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-7; PMID:15014018; http://dx.doi.org/10.1158/1078-0432.CCR-1103-3
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, et al.; EORTC melanoma group. adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-26; PMID:18620949; http://dx.doi.org/10.1016/S0140-6736(08)61033-8
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery. http://www.clinicaltrials.gov/ct2/show/NCT01274338?term=A+Phase+III+Randomized+Study+of+Adjuvant+Ipilimumab+Anti-CTLA4+Therapy&rank=1:ClinicalTrials.gov
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Taneja SS. Re: safety and activity of anti-PD-L1 antibody in patients with advanced cancer. J Urol 2012; 188:2148-9; PMID:23141220; http://dx.doi.org/10.1016/j.juro.2012.08.169
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Mario Sznol HMK, F Stephen Hodi, David F McDermott, Richard D Carvajal, Donald P Lawrence, Suzanne Louise Topalian, Michael B Atkins, John D Powderly, William Howard Sharfman, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31; 2013 (suppl; abstr CRA9006^) 2013.
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase 3 study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma (CheckMate 067). http://clinicaltrials.gov/ct2/show/NCT0184450
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-54; PMID:9547346; http://dx.doi.org/10.1084/jem.187.8.1349
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92:11810-3; PMID:8524854; http://dx.doi.org/10.1073/pnas.92.25.11810
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103; PMID:8837607; http://dx.doi.org/10.1038/nm1096-1096
   PubMed Web of Science ®Google Scholar
• Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 1998; 161:4842-51; PMID:9794417
   PubMed Web of Science ®Google Scholar
• Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165:1705-11; PMID:10903782; http://dx.doi.org/10.4049/jimmunol.165.3.1705
   PubMed Web of Science ®Google Scholar
• Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal RG. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:9334364; http://dx.doi.org/10.1084/jem.186.8.1247
   PubMed Web of Science ®Google Scholar
• Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186:1213-21; PMID:9334360; http://dx.doi.org/10.1084/jem.186.8.1213
   PubMed Web of Science ®Google Scholar
• Li J, Holmes LM, Franek KJ, Wagner TE, Wei Y. Murine tyrosinase expressed by a T7 vector in bone marrow-derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice. Cancer Gene Ther 2000; 7:1448-55; PMID:11129287; http://dx.doi.org/10.1038/sj.cgt.7700260
   PubMed Web of Science ®Google Scholar
• Wei Y, Li J, Chen WY, Yu X, Sticca RP, Wagner TE. Enhanced transgene expression and effective in vivo antitumor immune responses initiated by dendritic progenitors transfected with a nonviral T7 vector expressing a model tumor antigen. J Immunother 2000; 23:75-82; PMID:10687140; http://dx.doi.org/10.1097/00002371-200001000-00010
   PubMed Web of Science ®Google Scholar
• Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo Y, Sterry W, Walden P. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 2000; 85:618-26; PMID:10699939; http://dx.doi.org/10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7; PMID:9500606; http://dx.doi.org/10.1038/nm0398-321
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42; PMID:7804974; http://dx.doi.org/10.1002/1097-0142(19950101)75:1<34::AID-CNCR282075-0108>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res 1995; 139:337-48; PMID:7597302; http://dx.doi.org/10.1007/978-3-642-78771-3_26
   PubMedGoogle Scholar
• Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25:623-35; PMID:9865677
   PubMed Web of Science ®Google Scholar
• Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 1993; 690:120-34; PMID:8368731; http://dx.doi.org/10.1111/j.1749-6632.1993.tb44002.x
   PubMed Web of Science ®Google Scholar
• Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Maguire HC Jr. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998; 25:646-53; PMID:9865679
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr., Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15:2359-70; PMID:9196151
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61; PMID:9142127; http://dx.doi.org/10.1038/nm0597-558
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528.
   PubMed Web of Science ®Google Scholar
• Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans K, van Meirvenne S, Geldhof A, De Baetselier P, Urbain J, Leo O, et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998; 76:250-8; PMID:9537588; http://dx.doi.org/10.1002/(SICI)1097-0215(19980413)76:2<250::AID-IJC13>3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Cao X, Zhang W, Wang J, Zhang M, Huang X, Hamada H, Chen W. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 1999; 97:616-25; PMID:10457215; http://dx.doi.org/10.1046/j.1365-2567.1999.00823.x
   PubMed Web of Science ®Google Scholar
• Zhang JK, Li J, Zhang J, Chen HB, Chen SB. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroenterol 2003; 9:479-84; PMID:12632501
   PubMed Web of Science ®Google Scholar
• Kawada M, Ikeda H, Takahashi T, Ishizu A, Ishikura H, Katoh H, Yoshiki T. Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo. Int J Cancer 2003; 105:520-6; PMID:12712444; http://dx.doi.org/10.1002/ijc.11120
   PubMed Web of Science ®Google Scholar
• McConnell EJ, Pathangey LB, Madsen CS, Gendler SJ, Mukherjee P. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res 2002; 107:196-202; PMID:12429175; http://dx.doi.org/10.1006/jsre.2001.6497
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003; 170:1980-6; PMID:12574367; http://dx.doi.org/10.4049/jimmunol.170.4.1980
   PubMed Web of Science ®Google Scholar
• Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003; 109:300-7; PMID:12757626; http://dx.doi.org/10.1046/j.1365-2567.2003.01656.x
   PubMed Web of Science ®Google Scholar
• Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A 2000; 97:2715-8; PMID:10688917; http://dx.doi.org/10.1073/pnas.050587197
   PubMed Web of Science ®Google Scholar
• Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483-94; PMID:12691613; http://dx.doi.org/10.1089/104303403321467243
   PubMed Web of Science ®Google Scholar
• Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y. A Rapid, Novel Strategy to Induce Tumor Cell-Specific Cytotoxic T Lymphocyte Responses Using Instant Dendritomas. J Immunother (1991) 2001; 24:122-9; PMID:11449068; http://dx.doi.org/10.1097/00002371-200103000-00006
   PubMed Web of Science ®Google Scholar
• Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 2001; 50:456-62; PMID:11761439; http://dx.doi.org/10.1007/s002620100218
   PubMed Web of Science ®Google Scholar
• Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, Jakubchak S, Bouton-Verville H, Williamson J, Meyer K, Evans L, et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol Rep 2007; 18:665-71; PMID:17671717
   PubMed Web of Science ®Google Scholar
• Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 2006; 28:585-93; PMID:16465362
   PubMed Web of Science ®Google Scholar
• Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001; 2:193-202; PMID:12057119; http://dx.doi.org/10.1007/s11864-001-0033-5
   PubMedGoogle Scholar
• Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003; 61:314-9; PMID:12597937; http://dx.doi.org/10.1016/S0090-4295(02)02163-5
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699-708; PMID:15269142; http://dx.doi.org/10.1158/1078-0432.CCR-04-0347
   PubMed Web of Science ®Google Scholar
• Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235:540-9; PMID:11923611; http://dx.doi.org/10.1097/00000658-200204000-00013
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32; PMID:9500607; http://dx.doi.org/10.1038/nm0398-328
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-8; PMID:11522640
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62:5845-52; PMID:12384547
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-9; PMID:11731436
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195:1279-88; PMID:12021308; http://dx.doi.org/10.1084/jem.20012100
   PubMed Web of Science ®Google Scholar